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Abstract 
 
 Ultrasound imaging (US) is an accurate and reliable method used to diagnose 
tendinopathy. This systematic review aimed to identify common criteria and 
parameters used to diagnose tendinopathy, the methodological quality of studies, 
and the predictive value of US. Nineteen studies met the inclusion criteria, with the 
Achilles, quadriceps and patella tendons being investigated. Overall, there was 
significant heterogeneity between the criteria used to diagnose tendinopathy utilising 
US. The methodological quality of included studies was "good”. Additionally, meta-
analysis showed that US identified abnormalities were predictive of future symptoms, 
and classification of tendinopathy using three US defined parameters demonstrated 
a higher relative risk of developing clinical tendinopathy when compared to using two 
US defined parameters. Further research into the development of a standardised US 
criterion that incorporates both clinical and US findings is required to allow for 
greater consistency in the diagnosis of tendinopathy. 
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 3 
Introduction 1 
 2 
Tendinopathy is an umbrella term for the clinical presentation of tendon pain 3 
and dysfunction with accompanying presumed pathological structural change to the 4 
internal tendon matrix (Maffulli, et al. 1998, Plinsinga, et al. 2015, Rees, et al. 2009). 5 
It is frequently seen in clinical practice, with the most commonly affected tendons 6 
being the Achilles, patellar, rotator cuff and elbow extensors (McCreesh and Lewis 7 
2013, Rees, et al. 2009). Overuse tendon injuries account for 30-50% of all sports 8 
injuries (Scott and Ashe 2006).  The catalyst for the onset of tendinopathy can be 9 
due to both an increase (Ackermann and Renström 2012, Lewis 2009, Maffulli, et al. 10 
1998, Rio, et al. 2014, Scott, et al. 2015) and a decrease (Arnoczky, et al. 2007, 11 
Reeves, et al. 2005) in mechanical loading of the tendon. It is chronic in nature, with 12 
recovery ranging from 3-14 months (Bonde, et al. 2003, Khan, et al. 2000). Similarly, 13 
studies have shown that a minimum of 6-months is required to see significant 14 
structural change on imaging (de Vos, et al. 2011, Ryan, et al. 2010, Ryan, et al. 15 
2011). Although, there is some evidence that structural changes can be seen on 16 
imaging in a shorter time-frame (Docking, et al. 2016). 17 
 18 
 There have been alternate models to describe the pathogenesis of 19 
tendinopathy (Abate, et al. 2009, Arnoczky, et al. 2007, Cook and Purdam 2009, Fu, 20 
et al. 2010). Of these models, the continuum model of tendinopathy, as originally 21 
proposed by Cook and Purdam (Cook and Purdam 2009), has become a widely 22 
accepted theoretical base and method to stage tendinopathy (Cook and Purdam 23 
2009, Cook, et al. 2016, McCreesh and Lewis 2013, Rees, et al. 2014). The stages 24 
 4 
identified within this model are distinguished by specific clinical and imaging features 1 
(Cook, et al. 2016).  2 
 3 
There are two primary methods for the diagnosis of tendinopathy (Scott, et al. 4 
2013). Clinically, the diagnosis of tendinopathy is predominantly centred on the 5 
patient history and clinical examination (Coombes, et al. 2015, Lewis 2016, Lewis, et 6 
al. 2015, Malliaras, et al. 2015, Scase, et al. 2011, Scott, et al. 2013). In regard to 7 
specific tests that have been reported to aid the diagnosis of tendinopathy, two out of 8 
ten commonly used tests (pain on palpation and location of pain) were found to be 9 
sufficiently reliable and accurate when compared to ultrasound imaging (Hutchison, 10 
et al. 2013). While pain on palpation has been shown to be sensitive (56-84%) for 11 
reproducing clinical symptoms, it is not specific (47-73%) in identifying pathological 12 
structural change when compared to medical imaging (Cook, et al. 2001, Grimaldi, et 13 
al. 2017, Hutchison, et al. 2013). Furthermore, clinical tests alone do not allow 14 
clinician the ability to determine where their patient may be on the tendinopathy 15 
continuum as stages are primarily based off structural changes (Cook, et al. 2016). 16 
 17 
Imaging presents a method where structural changes within the tendon matrix 18 
can be identified. Both ultrasound imaging (US) and magnetic resonance imaging 19 
(MRI) are used to confirm the presence of structural tendon change in the clinical 20 
setting, with the choice of which technique to use based on clinician preference 21 
(Scott, et al. 2013). Furthermore, US has demonstrated better accuracy (Khan, et al. 22 
2003, Warden, et al. 2007), and sensitivity (Westacott, et al. 2011) when compared 23 
to MRI for assessing tendinopathy. Additionally, US has been shown to have good 24 
reliability (Ingwersen, et al. 2016) and is considered more patient-friendly and cost 25 
 5 
effective than MRI for the assessment of musculoskeletal conditions, with the ability 1 
for dynamic assessment and the measurement of neovascularisation (Lento and 2 
Primack 2008, Mapes-Gonnella 2013). 3 
 4 
 Although numerous studies have examined the sensitivity and accuracy of 5 
imaging in identifying tendinopathy (Docking, et al. 2015, Scott, et al. 2013), 6 
research utilising US has been limited to classifying tendon structural change with 7 
the use of subjective grading scores established on a multitude of pathological 8 
features (Docking, et al. 2015, Ellis and Manuel 2015). In a recent literature review 9 
(Ellis and Manuel 2015), the most commonly reported abnormal tendon matrix 10 
features, as seen with US, included echogenicity, fusiform swelling, tendon 11 
thickness, neovascularisation, fibrillation, calcification and intra-substance tears. 12 
 13 
  It has been proposed that abnormalities identified on US may be considered 14 
as a risk factor for the development of future symptoms (Cook, et al. 2016, McAuliffe, 15 
et al. 2016). However, due to the cross-sectional design of many imaging studies 16 
(McAuliffe, et al. 2016) and the variability in features measured (Ellis and Manuel 17 
2015), uncertainty remains as to the relevance of identified tendon structural 18 
abnormalities and their impact on the management of tendinopathy in populations 19 
where there is a high prevalence of tendon related pain (McAuliffe, et al. 2016). 20 
Although it is accepted that US identified tendon abnormalities can be considered a 21 
risk factor (Cook, et al. 2016, McAuliffe, et al. 2016), no study has investigated the 22 
predictability of varying classification systems utilising different US based 23 
parameters.  24 
 25 
 6 
 The lack of a homogenous and standardised US criterion for assessing 1 
tendon matrix change makes determining the clinical utility of US in the diagnosis 2 
and management of tendinopathy difficult. Identification of commonly used US 3 
parameters and classification systems, along with assessing the predictability of 4 
varying parameters, may aid in determining the clinical utility of US and lead to 5 
greater homogeneity within this topic area. Thus, the primary aim of this systematic 6 
review was to identify the US based tendinopathy classifications that are reported, 7 
including specific tendon matrix features measured. Following this review, the 8 
secondary aim was to appraise the methodological quality of the included studies.  9 
The final aim was to utilise meta-analysis to assess the predictive value of the 10 
different classification systems that were identified. 11 
 12 
Methods 13 
 14 
Study Design 15 
  16 
The study followed the methodology proposed in the Preferred Reporting 17 
Items for Systematic Reviews and Meta-Analysis (PRISMA) statement (Moher, et al. 18 
2009). Following the PRISMA guidelines, a detailed search strategy was developed 19 
and implemented up to August 2017.  20 
 21 
Eligibility Criteria 22 
 23 
 Studies were included if they met the following criteria: 24 
• Published full-length research articles in English with the full text available 25 
 7 
• Human participants (male or female) of any age, from any athletic or 1 
community background 2 
• Longitudinal (randomised or non-randomised) or observational 3 
(retrospective or prospective) study design 4 
• Minimum clinical follow-up over 24 hours as tendons demonstrate an 5 
immediate response to load on imaging (Koenig, et al. 2010, Rosengarten, 6 
et al. 2015) 7 
• Tendinopathy in any location  8 
• US as an outcome measure to assess tendon matrix changes (e.g. tendon 9 
thickness, echogenicity, collagen organisation, fibrillar pattern, 10 
vascularisation, etc.) 11 
• Graded or classified tendinopathy stage using either a nominal or ordinal 12 
scale  13 
 14 
Studies were excluded if they met the following criteria: 15 
• Patients who had other medical conditions that may affect outcome 16 
measures (e.g. Rheumatoid arthritis, diabetes mellitus) 17 
• Cross-sectional studies 18 
• Focused on tendon tear or rupture 19 
• Surgical interventions or injection therapies (corticosteroid or platelet 20 
rich plasma) as part of the treatment protocol 21 
 22 
Search Methods 23 
 24 
 8 
A detailed, multi-step search strategy using PRISMA guidelines, was 1 
conducted up to August 2017 to identify relevant studies regardless of publication 2 
date. The search was conducted in the following databases: Embase; PubMed; 3 
SPORTDiscus; EBSCOhost; CINAHL; ProQuest. In addition to the electronic 4 
database search, included articles reference lists were searched for additional 5 
articles. To ensure a wider search strategy of relevant articles, keywords were 6 
truncated to allow for variations in spelling, and combined using Boolean operators 7 
as outlined in Table 1. MeSH terms were also used to ensure review of relevant 8 
articles. Search strategies for databases were equivalent with the same keywords 9 
and Boolean operators, however slight adaptations were made depending on each 10 
databases’ respective characteristics. 11 
 12 
Study Selection 13 
 14 
Search results were imported to EndNote reference management software 15 
(EndNote X8.0.1, Clarivate Analytics, 22 Thomson Place, 36T3 Boston, MA 02210). 16 
Duplicate records were removed. Titles and abstracts of retrieved articles were 17 
screened for eligibility. After the initial screening, the full-text of relevant studies were 18 
retrieved for further analysis.  19 
 20 
Data Extraction 21 
 22 
Data extracted included specific details regarding the study design, authors, 23 
year of publication, population, intervention methodology, tendon location and length 24 
 9 
of follow-up. Specific data related to outcome measures included parameters 1 
measured and grading or classification system used. 2 
 3 
Assessment of Methodological Quality 4 
 5 
The Critical Appraisal Skills Programme (CASP) tool was used to assess 6 
methodological quality of included studies (Critical Appraisal Skills Programme 2017, 7 
Critical Appraisal Skills Programme 2017). Studies were assessed using the CASP 8 
toolkit independently by two researchers (WM and JF).  The CASP toolkit is 9 
comprised of eight separate checklists to be used depending on study design and 10 
enables researchers to critically assess the validity and relevance of published 11 
articles. The included articles were assessed for quality using the CASP Cohort 12 
Study Checklist (Critical Appraisal Skills Programme 2017) and the CASP 13 
Randomised Controlled Trial Checklist (Critical Appraisal Skills Programme 2017). 14 
The CASP Cohort Study Checklist (Critical Appraisal Skills Programme 2017) 15 
provides 12 questions to assess study quality. The first two questions are screening 16 
questions, while the next ten provide a framework to assess the results of the study, 17 
the study validity and relevance. Similarly, the CASP Randomised Controlled Trial 18 
Checklist (Critical Appraisal Skills Programme 2017) uses 11 questions to assess 19 
validity, results and applicability of studies, with the first two questions being 20 
screening questions.  21 
 22 
As was the method of a recent systematic review (McAuliffe, et al. 2016), 23 
questions seven, eight and nine in the CASP Cohort Study Checklist (Critical 24 
Appraisal Skills Programme 2017) and questions seven and eight in the CASP 25 
 10 
Randomised Controlled Trial Checklist (Critical Appraisal Skills Programme 2017) 1 
were combined into one question, as they were deemed to investigate similar areas. 2 
Most questions are answered with ‘yes’, ‘no’ or ‘can’t tell’. The CASP checklists do 3 
not provide a scoring system to appraise the quality of evidence (Critical Appraisal 4 
Skills Programme 2017, Critical Appraisal Skills Programme 2017). However, 5 
although there is a lack of consensus as to what criteria to appraise in quantitative 6 
research, it is recognised that quality issues should be highlighted by reviewers 7 
(Goldsmith, et al. 2007). For the purpose of this systematic review, a scoring system 8 
was developed where ‘1’ point was awarded for a ‘yes’ and ‘0’ points for a ‘no’, with 9 
the maximum score being 12 for the CASP Cohort Study Checklist (Critical Appraisal 10 
Skills Programme 2017) and 10 for the CASP Randomised Controlled Trial Checklist 11 
(Critical Appraisal Skills Programme 2017). 12 
 13 
Overall scores were calculated as a percentage and quality was rated 14 
according to the methods reported by Kennelly (2011) where grades were 15 
categorized as ‘poor’, ‘fair’ or ‘good’. Studies that scored ≥60% were considered as 16 
‘good’ quality, while studies that scored between 45%-59% were ‘fair’ and studies 17 
that scored <45% were considered ‘poor’, as has been reported in previous studies 18 
(Adhia, et al. 2013, Barrett, et al. 2014, May, et al. 2010, May, et al. 2006). To 19 
ensure consistency of critical appraisal, the criteria used for each question in the 20 
CASP checklist was agreed upon between the two reviewers (WM and JF) prior to 21 
commencement of the appraisal process. Inter-rater agreement for each question 22 
and overall was calculated using Cohen’s Kappa coefficient. 23 
 24 
Synthesis and Analysis  25 
 11 
 1 
To determine agreement between raters following the critical appraisal 2 
process, a Cohen’s Kappa was calculated using SPSS software package (IBM 3 
SPSS Statistics for Macintosh, Version 24.0. Armonk, NY: IBM Corp.). Where 4 
quantitative methods were appropriate to statistically pool data, a meta-analysis was 5 
performed using Review Manager software (Review Manger (RevMan) for 6 
Macintosh, Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane 7 
Collaboration, 2014). A random effects models using the Mantel-Haenszel method 8 
was used to determine pooled relative risk (RR) of developing symptomatic 9 
tendinopathy with 95% confidence intervals (CI). Studies were included in the meta-10 
analysis if they used similar methodology, reported on asymptomatic tendons that 11 
became symptomatic, and provided data on asymptomatic baseline structural 12 
changes and development of symptoms at follow-up. Studies were excluded from 13 
the meta-analysis if they included symptomatic tendons from baseline, used specific 14 
interventions as part of the rehabilitation process, or provided insufficient data on 15 
baseline or follow-up structural changes. RR was calculated for three subgroups; 1) 16 
tendon site (Achilles or patellar), 2) number of parameters used in classifications (3 17 
parameters or 2 parameters), and 3) number of parameters used for specific tendon 18 
location. 19 
 20 
The heterogeneity between studies was assessed using the I2 statistic. The I2 21 
value describes the percentage of variation across the studies that is due to 22 
heterogeneity rather than chance, ranging from 0-100%, where 0% shows no 23 
heterogeneity and increasing values show increasing heterogeneity (Higgins, et al. 24 
2003). I2 values of 25% indicate low, 50% moderate and 75% high heterogeneity 25 
 12 
(Higgins, et al. 2003). Similar to a previous systematic review (Smidt, et al. 2003), a 1 
RR >1.5 was considered clinically significant for the predictability of US identified 2 
abnormalities in asymptomatic tendons becoming symptomatic. RR was summarised 3 
using forest plots, while study and publication bias was assessed using funnel plots.  4 
 5 
 Where meta-analysis was not appropriate due to the heterogeneity of articles 6 
and criterion used to assess tendon matrix change on US, a qualitative approach 7 
was utilized. Results were synthesised to analyse tendon parameters measured, 8 
quality of evidence, predictive value of criteria and relationship to the continuum 9 
model of tendinopathy. This data synthesis was then used to inform and guide the 10 
development of the proposed criteria, with a greater weighting being placed on 11 
articles of ‘good’ quality and parameters that were predictive of tendinopathy. 12 
 13 
Results 14 
 15 
Search Results 16 
 17 
The search results are shown in the PRISMA Flow Diagram (Figure 1). After 18 
the removal of duplicates and screening of titles and abstracts against the inclusion 19 
criteria, the full-text of 68 articles was retrieved and assessed for inclusion in the 20 
systematic review. Of these, nineteen articles (Archambault, et al. 1998, Boesen, et 21 
al. 2012, Comin, et al. 2013, Cook, et al. 2001, Cook, et al. 2000, de Jonge, et al. 22 
2010, de Vos, et al. 2007, Fredberg and Bolvig 2002, Fredberg, et al. 2008, 23 
Giombini, et al. 2013, Gisslén and Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, 24 
et al. 2012, Jhingan, et al. 2011, Khan, et al. 1997, Khan, et al. 2003, Malliaras, et al. 25 
 13 
2010, Ooi, et al. 2015, Visnes, et al. 2015) met the inclusion criteria and were 1 
included in the systematic review. 2 
 3 
Characteristics of Included Studies 4 
 5 
 A detailed description of the included studies is provided in Table 2. Of the 6 
nineteen included studies, seventeen were cohort studies (Archambault, et al. 1998, 7 
Boesen, et al. 2012, Comin, et al. 2013, Cook, et al. 2001, Cook, et al. 2000, de Vos, 8 
et al. 2007, Fredberg and Bolvig 2002, Giombini, et al. 2013, Gisslén and Alfredson 9 
2005, Gisslén, et al. 2007, Hirschmüller, et al. 2012, Jhingan, et al. 2011, Khan, et al. 10 
1997, Khan, et al. 2003, Malliaras, et al. 2010, Ooi, et al. 2015, Visnes, et al. 2015) 11 
and two were randomised controlled trials (de Jonge, et al. 2010, Fredberg, et al. 12 
2008). While no limitations were placed on tendon location, all nineteen included 13 
studies investigated tendons in the lower limb, with the Achilles, patellar and 14 
quadriceps tendons assessed (Archambault, et al. 1998, Boesen, et al. 2012, Comin, 15 
et al. 2013, Cook, et al. 2001, Cook, et al. 2000, de Jonge, et al. 2010, de Vos, et al. 16 
2007, Fredberg and Bolvig 2002, Fredberg, et al. 2008, Giombini, et al. 2013, 17 
Gisslén and Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, et al. 2012, Jhingan, 18 
et al. 2011, Khan, et al. 1997, Khan, et al. 2003, Malliaras, et al. 2010, Ooi, et al. 19 
2015, Visnes, et al. 2015). Tendon matrix change was classified using either a 20 
nominal or ordinal scale. In a nominal scale, labels are descriptive, allowing for the 21 
counting but not ordering of data, while an ordinal scale allows for data to be ranked 22 
(Stevens 1946).  23 
 24 
 14 
A nominal grading scale was used in twelve of the included studies (Comin, et 1 
al. 2013, Cook, et al. 2001, Cook, et al. 2000, Fredberg and Bolvig 2002, Giombini, 2 
et al. 2013, Gisslén and Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, et al. 3 
2012, Jhingan, et al. 2011, Khan, et al. 1997, Malliaras, et al. 2010, Visnes, et al. 4 
2015), while an ordinal scale was used in the remaining seven studies (Archambault, 5 
et al. 1998, Boesen, et al. 2012, de Jonge, et al. 2010, de Vos, et al. 2007, Fredberg, 6 
et al. 2008, Khan, et al. 2003, Ooi, et al. 2015). The studies that used nominal scales 7 
classified tendon structural change as either ‘normal’ or ‘abnormal’ (Comin, et al. 8 
2013, Cook, et al. 2001, Cook, et al. 2000, Fredberg and Bolvig 2002, Giombini, et 9 
al. 2013, Gisslén and Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, et al. 2012, 10 
Jhingan, et al. 2011, Khan, et al. 1997, Malliaras, et al. 2010, Visnes, et al. 2015). 11 
Three studies that used an ordinal scale graded tendinopathy as ‘Grade 1’, ‘Grade 2, 12 
or ‘Grade 3’ (Archambault, et al. 1998, Khan, et al. 2003, Ooi, et al. 2015), while one 13 
classified change as ‘normal’, ‘slightly abnormal’ or ‘severely abnormal’ (Fredberg, et 14 
al. 2008). Two studies used a 5-point scale (de Jonge, et al. 2010, de Vos, et al. 15 
2007) and one used a 6-point scale (Boesen, et al. 2012). 16 
 17 
Study Scoring and Quality 18 
 19 
 Overall CASP results are summarised in Table 3. Inter-rater agreement was 20 
calculated for each question using Cohen’s Kappa. Overall, based on previously 21 
published guidelines (Fleiss 1981), Cohen’s Kappa was excellent at 0.93 for the 22 
seventeen cohort studies and perfect at 1.00 for the two randomised controlled trials. 23 
Disagreements were discussed, and a consensus drawn between the two raters. 24 
The quality of all studies was rated as ‘good’ according to the categories proposed 25 
 15 
by Kennelly (Kennelly 2011) and the criteria used in previous studies (Adhia, et al. 1 
2013, Barrett, et al. 2014, May, et al. 2010, May, et al. 2006). 2 
 3 
Synthesis of Evidence 4 
 5 
 A synthesis of evidence is provided in Table 4. Overall, there was significant 6 
heterogeneity between the parameters used to assess tendon matrix change and the 7 
ability to predict outcomes. Three studies (Boesen, et al. 2012, de Jonge, et al. 2010, 8 
de Vos, et al. 2007) measured only one parameter when assessing tendon matrix 9 
change, while six studies (Archambault, et al. 1998, Cook, et al. 2001, Cook, et al. 10 
2000, Fredberg and Bolvig 2002, Fredberg, et al. 2008, Khan, et al. 1997) used two 11 
parameters and the remaining ten studies (Comin, et al. 2013, Giombini, et al. 2013, 12 
Gisslén and Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, et al. 2012, Jhingan, 13 
et al. 2011, Khan, et al. 2003, Malliaras, et al. 2010, Ooi, et al. 2015, Visnes, et al. 14 
2015) used three parameters. No study included fibrillar pattern as a parameter to 15 
assess tendon matrix change. All studies were of good quality according to the 16 
previously stated scoring system. Additionally, no criteria were related to the stages 17 
of tendinopathy as proposed in the Cook and Purdam (Cook and Purdam 2009) 18 
continuum model. There were mixed results when looking at the predictive value of 19 
the individual criterion, with nine studies (Boesen, et al. 2012, Comin, et al. 2013, 20 
Cook, et al. 2001, de Jonge, et al. 2010, de Vos, et al. 2007, Hirschmüller, et al. 21 
2012, Jhingan, et al. 2011, Khan, et al. 2003, Ooi, et al. 2015) indicating 22 
abnormalities measured on US are unable to predict of clinical outcome, while the 23 
remaining ten studies (Archambault, et al. 1998, Cook, et al. 2000, Fredberg and 24 
Bolvig 2002, Fredberg, et al. 2008, Giombini, et al. 2013, Gisslén and Alfredson 25 
 16 
2005, Gisslén, et al. 2007, Khan, et al. 1997, Malliaras, et al. 2010, Visnes, et al. 1 
2015) showed US can be a predictor of clinical outcome. 2 
 3 
Echogenicity 4 
 5 
Echogenicity was the equal most commonly measured structural change on 6 
US with results summarised in Table 5. Of the included studies, sixteen measured 7 
echogenicity as a variable for structural change (Archambault, et al. 1998, Comin, et 8 
al. 2013, Cook, et al. 2001, Cook, et al. 2000, Fredberg and Bolvig 2002, Fredberg, 9 
et al. 2008, Giombini, et al. 2013, Gisslén and Alfredson 2005, Gisslén, et al. 2007, 10 
Hirschmüller, et al. 2012, Jhingan, et al. 2011, Khan, et al. 1997, Khan, et al. 2003, 11 
Malliaras, et al. 2010, Ooi, et al. 2015, Visnes, et al. 2015). Overall, abnormal 12 
echogenicity was not defined in thirteen studies (Archambault, et al. 1998, Comin, et 13 
al. 2013, Cook, et al. 2001, Cook, et al. 2000, Giombini, et al. 2013, Gisslén and 14 
Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, et al. 2012, Khan, et al. 1997, 15 
Khan, et al. 2003, Malliaras, et al. 2010, Ooi, et al. 2015, Visnes, et al. 2015). Two 16 
studies (Fredberg and Bolvig 2002, Jhingan, et al. 2011), defined abnormal 17 
echogenicity as the presence of a hypoechoic region larger than 1mm in size, with 18 
the remaining study (Fredberg, et al. 2008) using different values for the Achilles 19 
tendon (0.5mm) and patellar tendon (1mm). 20 
 21 
Thickness 22 
 23 
 All studies that measured echogenicity also measured tendon thickness 24 
(Archambault, et al. 1998, Comin, et al. 2013, Cook, et al. 2001, Cook, et al. 2000, 25 
 17 
Fredberg and Bolvig 2002, Fredberg, et al. 2008, Giombini, et al. 2013, Gisslén and 1 
Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, et al. 2012, Jhingan, et al. 2011, 2 
Khan, et al. 1997, Khan, et al. 2003, Malliaras, et al. 2010, Ooi, et al. 2015, Visnes, 3 
et al. 2015), with results presented in Table 6. Similarly, thirteen studies 4 
(Archambault, et al. 1998, Comin, et al. 2013, Cook, et al. 2001, Cook, et al. 2000, 5 
Giombini, et al. 2013, Gisslén and Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, 6 
et al. 2012, Khan, et al. 1997, Khan, et al. 2003, Malliaras, et al. 2010, Ooi, et al. 7 
2015, Visnes, et al. 2015) determined the presence of increased thickness as 8 
‘abnormal’, however, cut-off values were not defined. Two studies (Fredberg and 9 
Bolvig 2002, Jhingan, et al. 2011) used a defined thickness as an increase of 1mm 10 
when related to the normal distal part of the tendon, while one study (Fredberg, et al. 11 
2008) classified tendon thickening >0.5mm in the Achilles tendon and thickening 12 
>1mm in the patellar tendon as ‘abnormal’. 13 
 14 
Vascularity 15 
 16 
 Vascularity was measured in thirteen of the included studies (Boesen, et al. 17 
2012, Comin, et al. 2013, de Jonge, et al. 2010, de Vos, et al. 2007, Giombini, et al. 18 
2013, Gisslén and Alfredson 2005, Gisslén, et al. 2007, Hirschmüller, et al. 2012, 19 
Jhingan, et al. 2011, Khan, et al. 2003, Malliaras, et al. 2010, Ooi, et al. 2015, 20 
Visnes, et al. 2015). An outline of the criteria used to assess vascularity is provided 21 
in Table 7. As outlined in Table 7, ten studies (Boesen, et al. 2012, de Jonge, et al. 22 
2010, de Vos, et al. 2007, Giombini, et al. 2013, Gisslén and Alfredson 2005, 23 
Gisslén, et al. 2007, Hirschmüller, et al. 2012, Malliaras, et al. 2010, Ooi, et al. 2015, 24 
Visnes, et al. 2015) used varying scales to define ‘abnormal’ vascularity. The 25 
 18 
remaining three studies (Comin, et al. 2013, Jhingan, et al. 2011, Khan, et al. 2003) 1 
used the presence of vascularity, with undefined parameters, to determine whether a 2 
tendon was classified as ‘abnormal’.  3 
 4 
Meta-analysis 5 
 6 
 Nine of the nineteen included studies were eligible for meta-analysis due to 7 
similarities in characteristics (Cook, et al. 2001, Cook, et al. 2000, Giombini, et al. 8 
2013, Gisslén and Alfredson 2005, Gisslén, et al. 2007, Jhingan, et al. 2011, Khan, 9 
et al. 1997, Khan, et al. 2003, Ooi, et al. 2015). The remaining ten studies could not 10 
be included due to insufficient data on the development of symptoms, significant 11 
differences in study design and methodology, or the inclusion of symptomatic 12 
tendons at baseline. Overall, Figure 2 demonstrates that tendon abnormalities on US 13 
may be predictive of the development of future symptoms in both the patellar and 14 
Achilles tendons (RR=4.78, 95% CI 2.49-9.15) with low heterogeneity between 15 
studies (I2=0%). 16 
 17 
Predictive value of parameters 18 
 19 
 Six studies (Giombini, et al. 2013, Gisslén and Alfredson 2005, Gisslén, et al. 20 
2007, Jhingan, et al. 2011, Khan, et al. 2003, Ooi, et al. 2015) used three 21 
parameters (echogenicity, thickness, vascularisation), while three studies (Cook, et 22 
al. 2001, Cook, et al. 2000, Khan, et al. 1997) used two parameters (echogenicity 23 
and thickness) when assessing structural change in patellar and Achilles tendons on 24 
US. Three parameters were found to have an increased risk of developing symptoms 25 
 19 
(RR=6.49, 95% CI 2.49-16.94) when compared to those studies using two 1 
parameters (RR=3.66, 95% CI 1.15-11.62). I2 values demonstrated low 2 
heterogeneity across subgroups (3 parameters I2=7%, 2 parameters I2=6%). This 3 
data is displayed in Figure 3. 4 
 5 
In the patellar tendon, three studies (Giombini, et al. 2013, Gisslén and 6 
Alfredson 2005, Gisslén, et al. 2007) used three parameters to assess structural 7 
change, while three studies (Cook, et al. 2001, Cook, et al. 2000, Khan, et al. 1997) 8 
assessed change using two parameters. Figure 4 demonstrates that three 9 
parameters (RR=10.42, 95% CI 2.34-46.37) may indicate an increased risk of future 10 
symptoms when compared to the use of two parameters (RR=3.03, 95% CI 1.15-11 
7.97). I2 analysis showed low heterogeneity across both subgroups (3 parameters 12 
I2=20%, 2 parameters I2=0%). All four studies (Giombini, et al. 2013, Jhingan, et al. 13 
2011, Khan, et al. 2003, Ooi, et al. 2015) assessing the Achilles tendon used three 14 
parameters and found an increased risk for developing symptoms (RR=5.45, 95% CI 15 
1.62-18.37). Heterogeneity was low between the studies (I2=0%).  16 
 17 
Statistical significance was found for the predictive value of US assessment of 18 
the tendon matrix for both the Achilles (p=0.006) and patellar (p=0.0001) tendons. 19 
There was no statistical difference between the two groups (p=0.80). Similarly, both 20 
3 parameters (p=0.0001) and 2 parameters (p=0.03) were determined to be 21 
statistically significant for predicting symptom development without a statistical 22 
difference between the two groups (p=0.45). In the patellar tendon, there was a 23 
statistical significance for the predictive value of both 3 parameters (p=0.002) and 2 24 
parameters (0.02), with no statistical difference between groups (p=0.17). Funnel 25 
 20 
plot analysis demonstrated no publication bias for all subgroup analysis (Figures 5, 6 1 
and 7). 2 
 3 
Discussion 4 
 5 
There is considerable debate regarding the clinical utility of imaging in 6 
tendinopathy (Docking, et al. 2015). There are two important issues to consider 7 
which have led to this debate.  The first issue is that in some studies abnormal 8 
structural tendon changes, as seen with US, have been reported in up to 59% of 9 
asymptomatic individuals (Brasseur, et al. 2004, Cook, et al. 1998, Fredberg and 10 
Bolvig 2002, Giombini, et al. 2013, Hirschmüller, et al. 2012, Khan, et al. 1997, 11 
Leung and Griffith 2008).  It is therefore apparent that there is a disparity that can be 12 
seen between the findings of imaging versus the clinical presentation (Fredberg, et 13 
al. 2004). Secondly, although numerous studies have examined the sensitivity and 14 
accuracy of imaging in identifying tendinopathy (Docking, et al. 2015, Scott, et al. 15 
2013), there is a lack of a valid clinical gold standard for diagnosing tendinopathy 16 
with which to reliably compare findings (Docking, et al. 2015). Additionally, with such 17 
a wide variety of classification systems and different imaging features reported, there 18 
appears to be a lack of agreement of an acceptable criterion or classification to 19 
match structural changes seen on US with the clinical stages of tendinopathy (Ellis 20 
and Manuel 2015). Furthermore, in the clinical setting, sonographers do not appear 21 
to use or refer to the continuum model of tendinopathy when diagnosing tendon 22 
disorders. Classifying patients according to structural changes, in addition to clinical 23 
symptoms, may allow the clinician to direct treatment to the key limiting factors (pain, 24 
function or load capacity) (Cook, et al. 2016, Scase, et al. 2011). 25 
 21 
 1 
Classification of tendinopathy 2 
 3 
 The primary aim of this systematic review was to identify the current methods 4 
used to classify tendinopathy using US. To the authors’ knowledge, this is the first 5 
systematic review and meta-analysis to focus specifically on current US parameters 6 
used to measure structural change in tendinopathy and the methods of classifying 7 
tendinopathy according to these parameters. We found that there is a distinct lack of 8 
homogeneity in the criteria used when assessing tendinopathy using US. While there 9 
is significant inconsistency in the currently used US tendinopathy classification 10 
methods, common US parameters used to measure structural change can be 11 
identified. These results align with those of Ellis and Manuel (Ellis and Manuel 2015), 12 
which demonstrated significant variability in both the overall classification scales 13 
used, and individual parameters measured from studies that examined tendinopathy 14 
with US. Additionally, this review demonstrated that there is a lack of a relationship 15 
between the classification systems employed clinically, and the widely accepted 16 
continuum model (Cook and Purdam 2009) of tendinopathy.  17 
  18 
Quality of Included Studies 19 
 20 
 One of the secondary aims of this literature review was to assess the 21 
methodological quality of the literature. According to the previously described quality 22 
scoring system and, as presented in Table 3, all included studies were determined to 23 
be of good methodological quality. The main areas of concern within the 24 
methodological quality of included studies was in the minimisation of bias (Comin, et 25 
 22 
al. 2013, Jhingan, et al. 2011, Khan, et al. 2003, Malliaras, et al. 2010), control of 1 
confounding factors (Archambault, et al. 1998, Comin, et al. 2013, Cook, et al. 2001, 2 
de Vos, et al. 2007, Fredberg and Bolvig 2002, Gisslén and Alfredson 2005, Gisslén, 3 
et al. 2007, Jhingan, et al. 2011, Khan, et al. 2003, Malliaras, et al. 2010), adequate 4 
follow-up (Archambault, et al. 1998, Hirschmüller, et al. 2012) and the presentation 5 
of results (Gisslén and Alfredson 2005, Gisslén, et al. 2007). Additionally, the main 6 
weaknesses of the included randomised controlled trials were concerned with 7 
recording of drop-outs (Fredberg, et al. 2008), blinding (de Jonge, et al. 2010, 8 
Fredberg, et al. 2008), and the similarity of treatment and control groups (Fredberg, 9 
et al. 2008). These results align with those of other systematic reviews (McAuliffe, et 10 
al. 2016) and provide a methodologically sound base for future research.  11 
 12 
Predictive value of US based classification systems 13 
 14 
A secondary aim of this review was to assess the predictive value of different 15 
US classification methods for the development of future symptoms. Overall, meta-16 
analysis demonstrated that US identified tendon abnormalities may present an 17 
increased risk (RR=4.78) for the development of future symptoms in Achilles and 18 
patellar tendinopathy. This aligns with the systematic review by McAuliffe et al. 19 
(2016), who demonstrated US identified abnormalities were predictive (RR=4.97) for 20 
the development of symptomatic lower limb tendinopathy. However, further sub-21 
group analysis according to parameters measured, showed significant differences to 22 
the predictive value of US. Notably, when measuring tendon matrix changes using 23 
US, the number of parameters measured may influence the predictive value of US in 24 
asymptomatic patients.  25 
 23 
 1 
Meta-analysis demonstrated that including three parameters (echogenicity, 2 
thickness and vascularity; RR=6.49) was more predictive than those using two 3 
parameters (echogenicity and thickness; RR=3.66) for the development of future 4 
symptoms in the lower limb. This was highlighted further when looking at the patellar 5 
tendon where RR was considerably higher when using three parameters (RR=10.49) 6 
compared to two parameters (RR=3.03). These results differ to those of McAuliffe et 7 
al. (2016) in that McAuliffe et al. (2016) demonstrated US identified abnormalities 8 
were a risk factor for the development of tendinopathy in both the Achilles and 9 
patella tendons. However, these results indicated that by utilising more parameters 10 
to define tendon abnormalities using US, the RR of developing future clinical 11 
tendinopathy may be increased. To the authors knowledge, this is the first research 12 
to investigate the impact of individual US parameters on the predictive value of 13 
tendinopathy. 14 
 15 
The synthesis of evidence illustrates that there is still debate as to the 16 
predictive value of US, with 53% of included studies determining US findings were 17 
predictive of future symptoms. Hirschmüller et al. (2012) found that 18 
neovascularisation Grade 1 may be predictive (odds ratio(OR) 6.9, 95% CI 2.6-18.8, 19 
p=0.0001) of future symptoms, however, hypoechogenicity, spindle-shaped 20 
thickening, and neovascularisation Grade 2-3 were not predictive (p>0.05). 21 
Whereas, Comin et al. (2013) reported moderate to severe hypoechoic regions may 22 
be predictive of symptoms in both the patellar and Achilles tendons (Fisher’s exact 23 
p=0.038). However, intratendon defects (patellar p=0.166, Achilles p=0.403) and 24 
neovascularisation (patellar p=0.342, Achilles 0.089) were not statistically significant 25 
 24 
for predicting symptoms. Additionally, Boesen et al. (2012) found no association 1 
between pain and abnormal neovascularisation at the end of a volleyball season with 2 
35% of painful tendons demonstrating abnormal flow. Similarly, de Jonge et al. 3 
(2010) demonstrated no significant difference in VISA-A scores between patients 4 
with and without neovascularisation at baseline (p=0.71), while de Vos et al. (2007), 5 
reported no statistical difference in the predictive value of neovascularisation when 6 
compared to both the VAS (p=0.053) and VISA-A (p=0.147).  7 
 8 
Conversely, Fredberg and Bolvig (2002) reported abnormal US had a 17% 9 
risk of developing symptomatic jumper’s knee and 45% risk of developing 10 
symptomatic Achilles tendinopathy. Similarly, Fredberg et al. (2008) demonstrated 11 
an abnormal US had a RR of 2.8 (95% CI, 1.6-4.9; p=0.002) in the Achilles tendon 12 
and RR of 2.2 (95% CI, 0.9-5.7; p=0.09) for the patellar tendon. Additionally, 13 
Malliaras et al. (2010) determined there was an increased probability of pain in 14 
tendons with both hypoechoic regions (59%) and diffuse thickening (43%). This is 15 
supported by Visnes et al. (2015) with both hypoechogenicity (OR 3.3, 95% CI 1.1-16 
9.2) and neovascularisation (OR 2.7, 95% CI 1.1-6.5) increasing the risk of 17 
developing symptomatic jumper’s knee.  18 
 19 
This variability in the reported results may be explained by two important 20 
factors. Firstly, research utilising US has been limited to classifying tendon structural 21 
change with the use of subjective grading scores established on a multitude of 22 
pathological features (Docking, et al. 2015, Ellis and Manuel 2015). Objective 23 
measurement of tendon structural change, seen with US, has been restricted to 24 
measuring dimensions such as tendon diameter, cross-sectional area of the tendon 25 
 25 
and number or size of hypoechoic regions (Docking, et al. 2015). Secondly, although 1 
numerous studies have examined the sensitivity and accuracy of US in identifying 2 
tendinopathy (Docking, et al. 2015, Scott, et al. 2013), there is a lack of a valid 3 
clinical gold standard for diagnosing tendinopathy, making assessing the clinical 4 
utility of US difficult (Docking, et al. 2015, McAuliffe, et al. 2016). 5 
 6 
Limitations 7 
 8 
 The exclusion of grey literature may increase the risk of publication bias 9 
(Conn, et al. 2003). It is also possible that non-English articles that may have met the 10 
inclusion criteria were missed. However, there is no evidence of systematic review 11 
bias form language restrictions (Morrison, et al. 2012). The exclusion of promising 12 
methods of US, such as elastography, may have an effect on publication bias. 13 
However, although early research shows promise as an adjunct to standard US (Ooi, 14 
et al. 2014), evidence is limited to smaller cross-sectional studies and there are 15 
some technical challenges to producing high-quality, reproducible elastograms 16 
(Domenichini, et al. 2017, Ooi, et al. 2014, Ryu and Jeong 2017). Moreover, as 17 
elastography is a recent development, many commercial US units lack the ability to 18 
assess this feature. A better understanding of fundamental properties of 19 
elastography (Ryu and Jeong 2017) and standardisation of imaging protocols (Ooi, 20 
et al. 2014) may allow future research to incorporate this technique into the US 21 
assessment of tendon matrix change. Additionally, study quality was assessed using 22 
the CASP tool (Critical Appraisal Skills Programme 2017, Critical Appraisal Skills 23 
Programme 2017), which does not utilise a scoring system to grade study quality, 24 
thus one was developed for the purpose of the review. The selection of quality 25 
 26 
appraisal tool may impact review conclusions (Voss and Rehfuess 2013), however, 1 
this was addressed by using two independent reviewers and determining inter-rater 2 
agreement for each question on the checklist.  3 
 4 
Implications for future research 5 
 6 
 Given the complexity of the relationship between structure, dysfunction and 7 
pain in tendinopathy, there is scope to develop a standardised method to assess 8 
tendon structural change on US, incorporating a number of parameters, and allowing 9 
for greater consistency in the diagnosis of tendinopathy. Based on the results of this 10 
systematic review and meta-analysis, future criteria for diagnosing tendinopathy 11 
using US should include measures of all three parameters (tendon thickness, 12 
echogenicity and vascularity) when assessing tendon structural change. 13 
Furthermore, there is a need for further studies to assess the validity of developing a 14 
clinical gold standard for the diagnosis of tendinopathy that incorporates both clinical 15 
and US findings to formulate a diagnosis of tendinopathy.  Additionally, in order to 16 
better integrate clinical and US findings, there is an opportunity to develop a method 17 
that merges the continuum model with US parameters to form an overall criteria that 18 
allows for greater consistency in the diagnosis of tendinopathy. Using the results of 19 
this literature review, an ordinal scale may be developed to diagnose tendinopathy 20 
using US as ‘normal’, ‘reactive/early dysrepair’ or ‘late dysrepair/degenerative’ to 21 
better align with the continuum model (Ellis and Manuel, 2015, Scase, et al. 2011). 22 
However, cut-off values would need to be determined to distinguish between the 23 
different stages within the continuum. 24 
 25 
 27 
Conclusions 1 
 2 
 This review demonstrates that there is significant variability in the US based 3 
criteria used to diagnose tendinopathy. Notably, US is predictive of the development 4 
of future clinical symptoms. Furthermore, the assessment of tendon structural 5 
change using three parameters revealed a higher RR when compared to using two 6 
parameters, indicating the predictive value of using three parameters. Furthermore, 7 
as imaging is one component of the clinical picture, there is scope to for future 8 
research to develop a standardised criterion that incorporates both clinical and US 9 
features to diagnose tendinopathy. This has the potential to improve the monitoring 10 
and clinical management of tendinopathies. 11 
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Table 1: Search strategy used for database search 
Database Search Strategy 
ProQuest 
((mesh(tendinopathy) OR all(tendinopath* OR tendonopath* 
OR tendinitis OR tendinosis)) AND ((mesh(ultrasonography) 
OR all(ultrasonograph* OR ultrasound OR sonograph*)) AND 
all(classification OR classify* OR grade OR grading OR stage 
OR staging OR characteris* OR characteriz*) 
PubMed 
(((("Tendinopathy"[Mesh]) AND (tendinopath* OR 
tendonopath* OR tendinitis OR tendinosis)) AND 
"Ultrasonography"[Mesh]) AND (ultrasonograph* OR 
ultrasound OR sonograph*)) AND (classification OR classify* 
OR grade OR grading OR stage OR staging OR characteris* 
OR characteriz*) 
Embase 
(‘tendinitis’/exp OR  tendinopath* OR tendonopath* OR 
tendinitis OR tendinosis) AND (‘echography’/exp OR  
ultrasonograph* OR ultrasound OR sonograph*) AND  
classification OR classify* OR grade OR grading OR stage OR 
staging OR characteris* OR characteriz* 
CINAHL 
(MH "Tendinopathy+" OR tendinopath* OR tendonopath* OR 
tendinitis OR tendinosis) AND (MH "Ultrasonography+" OR  
ultrasonograph* OR ultrasound OR sonograph*) AND  
classification OR classify* OR grade OR grading OR stage OR 
staging OR characteris* OR characteriz* 
SPORTDiscus 
(DE "TENDINITIS" OR DE "ACHILLES tendinitis" OR DE 
"CALCIFIC tendinitis" OR  tendinopath* OR tendonopath* OR 
tendinitis OR tendinosis) AND (DE "ULTRASONIC imaging" 
OR DE "DIAGNOSTIC ultrasonic imaging" OR  
ultrasonograph* OR ultrasound OR sonograph*) AND 
(classification OR classify* OR grade OR grading OR stage 
OR staging OR characteris* OR characteriz*) 
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Table 2: Characteristics of included studies 
Author Study 
Design 
Demographics Population Tendon US 
Structural 
Changes 
Classification Ultrasound 
Imaging & 
Follow Up 
Archambault, 
et al. (1998)  
Cohort 
Study 
N = 33 (M - 20, F - 
13) 
Mean Age - 35.8 
(range 18-59) 
Sports 
Medicine 
Clinic 
 
Achilles Echogenicity 
Thickness 
1: Normal (parallel margins, 
homogeneous) 
2: Enlarged tendon (bowed margins, 
homogeneous) 
3: Hypoechoic (with or without 
enlargement) 
US: Initial visit  
Follow Up: 
24.3 months 
Boesen, et al. 
(2012)  
Cohort 
Study 
N = 86 (M - 56, F - 
30) 
Mean Age - 21.7 
(range N/A) 
Badminton Achilles 
Patellar 
Quadriceps 
Vascularity 0: no Doppler 
1: 1 or 2 tiny foci 
2: <5% colour ROI 
3: 5-24% colour ROI 
4: 25-49% colour ROI 
5: >50% colour ROI 
US: Initial & 
Follow Up  
Follow-up: 8 
months 
 
Comin, et al. 
(2013)  
Cohort 
Study 
N = 79 (M - 35, F - 
44) 
Mean Age - 27.6 
(range 18-40) 
Ballet 
Dancers 
Achilles 
Patellar 
Echogenicity 
Thickness 
Vascularity 
Calcification 
Normal 
Abnormal: presence of  
(1) hypoechogenicity (undefined), or 
(2) incr. thickness (undefined), or 
(3) vascularity (undefined), or 
(4) intratendon calcification (undefined) 
US: Initial visit  
Follow Up: 24 
months 
Cook, et al. 
(2000)  
Cohort 
Study 
N = 26 (M - 8, F - 
18) 
Mean Age - N/A 
(range 14-18) 
Junior 
Basketball 
Patellar Echogenicity 
Thickness 
Normal 
Abnormal: presence of 
(1) hypoechoic region, or 
(2) fusiform swelling 
(all undefined) 
US: Initial & 
Follow Up  
Follow Up: 16 
months (12-24 
months) 
Cook, et al. 
(2001)  
Cohort 
Study 
N = 24 (M -24) 
Mean Age - 29.8 
(at follow-up) 
Football, 
Basketball, 
Cricket 
Patellar Echogenicity 
Thickness 
Normal 
Abnormal: presence of 
(1) hypoechoic region, or 
(2) fusiform swelling 
(all undefined) 
US: Initial & 
Follow Up  
Follow Up: 
47.1 months 
(32-80 
months) 
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de Jonge, et 
al. (2010)  
RCT N = 50 (63 
tendons - M - 26, 
F -37) 
Mean Age - 44.6 
(range 26-59) 
Sports 
Medicine 
Clinic  
 
Achilles Vascularity 0: no vessels 
1: one vessel mostly in anterior part 
2: one/two vessels throughout tendon 
3: three vessels throughout tendon 
4: >3 large vessels throughout tendon 
US: Initial & 
Follow Up 
Follow Up: 12 
months 
de Vos, et al. 
(2007)  
Cohort 
Study 
N = 52 (63 
tendons - M - 26, 
F -37) 
Mean Age - 44.6 
(range 26-59) 
Sports 
Medicine 
Clinic  
 
Achilles Vascularity 0: no vessels 
1+: one vessel mostly in anterior part 
2+: one/two vessels throughout tendon 
3+: three vessels throughout tendon 
4+: >3 large vessels throughout tendon 
US: Initial & 
Follow Up 
Follow Up: 12 
weeks 
Fredberg and 
Bolvig (2002)  
Cohort 
Study 
N = 54 (M - 54) 
Mean Age - N/A 
(range 18-35) 
Soccer  Achilles 
Patellar 
Echogenicity 
Thickness 
Normal 
Abnormal: presence of 
(1)   >1mm thickening 
(2)   > 1mm hypoechoic region 
US: Initial & 
Follow Up  
Follow Up: 12 
months 
Fredberg, et al. 
(2008)  
RCT N = 207 (M - 207) 
Mean Age - 25.0 
(range 17-37) 
Soccer  Achilles 
Patellar 
Echogenicity 
Thickness 
Normal 
Slightly Abnormal: 
(1)   Thickening 0.5-1mm 
(2)   Hypoechoic region 1-2mm 
Severely Abnormal: 
(1)   Thickening >1mm  
(2)   Hypoechoic region >2mm  
US: Initial & 
Follow Up  
Follow Up: 12 
months 
Giombini, et al. 
(2013) 
Cohort 
Study 
N = 37 (M - 15, F - 
22) 
Mean Age - 27 
(range 16-36) 
Fencers Achilles 
Patellar 
Quadriceps 
Echogenicity 
Thickness 
Vascularity 
Normal 
Abnormal:  presence of 
(1) Focal/Diffuse thickening (undefined) 
(2) Focal/Diffuse hypoechogenicity 
(undefined) 
(3) Vascularity >2 (0- no flow, 1- flow 
outside tendon, 2- 1 or 2 vessels inside 
tendon, 3- multiple vessels inside 
tendon) 
US: Initial & 
Follow Up 
Follow Up: 
Avg. 3 years 
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Gisslén and 
Alfredson 
(2005)  
Cohort 
Study 
N = 60 (M - 29, F - 
31) 
Mean Age - 17.2 
(range 15-19) 
Junior 
Volleyball 
Patellar Echogenicity 
Thickness 
Vascularity 
Normal 
Abnormal:  presence of 
(1) Increased thickness (undefined) 
(2) Hypoechogenicity (undefined) 
(3) Vascularity >2 (0- no flow, 1- flow 
outside tendon, 2- 1 or 2 vessels inside 
tendon, 3- multiple vessels inside 
tendon) 
US: Initial & 
Follow Up  
Follow Up: 7 
months 
Gisslén, et al. 
(2007)  
Cohort 
Study 
N = 22 (M - 11, F - 
11) 
Mean Age - 16.3 
(range 15-16 at 
start) 
Junior 
Volleyball 
Patellar Echogenicity 
Thickness 
Vascularity 
Normal 
Abnormal: presence of 
(1) Increased thickness (undefined) 
(2) Hypoechogenicity (undefined) 
(3) Vascularity >2 (0- no flow, 1- flow 
outside tendon, 2- 1 or 2 vessels inside 
tendon, 3- multiple vessels inside 
tendon) 
US: Initial, 
Regular 
intervals & 
Follow Up (6 
total) 
Follow Up: 3 
years 
Hirschmüller, 
et al. (2012)  
Cohort 
Study 
N = 634 (M - 425, 
F - 209) 
Mean Age - 41.2 
(range 17-73) 
Long 
Distance 
Runners 
Achilles Echogenicity 
Thickness 
Vascularity 
Normal 
Abnormal: presence of 
(1) Tendon thickening (undefined) 
(2) Hypo/hyper echogenicity 
(undefined) 
(3) Vascularity (0 – no Doppler, 1 – 1 or 
2 tiny foci, 2 – <5% colour ROI, 3 – 5-
24% colour ROI, 4 – 25-49% colour 
ROI, 5 – 50% colour ROI) 
US: Initial visit  
Follow Up: 12 
months 
Jhingan, et al. 
(2011)  
Cohort 
Study 
N = 18 (M -18) 
Mean Age - 23.5 
(range 22-27.5) 
Soccer  Achilles Echogenicity 
Thickness 
Vascularity 
Normal 
Abnormal: presence of 
(1) Thickening (> 1mm) 
(2) Hypoechogenicity (> 1mm)  
(3) Paratendon Blurring 
(4) Vascularity (undefined) 
US: Initial visit  
Follow Up: 12 
months 
Khan, et al. 
(1997)  
Cohort 
Study 
N = 30 (F - 30) 
Mean Age – 24 
(range N/A) 
Basketball Patellar Echogenicity 
Thickness 
Normal 
Abnormal: presence of 
(1) Increased thickness (undefined) 
(2) Hypoechogenicity (undefined) 
US: Initial & 
Follow Up  
Follow Up: 
18.3 months 
(range 12-34 
months) 
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Khan, et al. 
(2003)  
Cohort 
Study 
N = 45 (M - 27, F - 
18) 
Mean Age - 42 
(range 20-66) 
Sports 
Medicine 
Centre 
 
Achilles Echogenicity 
Thickness 
Vascularity 
1: Normal 
2: Thickened (>6mm) homogenous 
echotexture 
3: Hypo/Hyperechoic areas 
with/without thickening (>6mm) 
Vascularity: normal or abnormal 
US: Initial & 
12 months 
Follow Up: 24 
months 
Malliaras, et al. 
(2010) 
Cohort 
Study 
N = 58 (M -36, F - 
22) 
Mean Age - 37.3 
(range N/A) 
Volleyball  Patellar Echogenicity 
Thickness 
Vascularity 
Normal 
Abnormal: presence of 
Diffuse Thickening (undefined) 
Hypoechogenicity (undefined) 
Vascularity min 1 vessel >1mm in 
length in sagittal plane 
US: Initial & 
Monthly 
Follow Up:  5 
months 
Ooi, et al. 
(2015)  
Cohort 
Study 
N = 41 (M - 25, F- 
16) 
Mean Age - 37.3 
(range N/A) 
Runners 
 
Achilles Echogenicity 
Thickness 
Vascularity 
1: Normal 
2: heterogeneous echotexture 
(undefined), bowed tendon  
margins (undefined), mild 
neovascularisation (1 or 2 
intratendinous vessels >1mm in length) 
3: marked thickening (undefined), 
discrete hypoechoic areas (undefined), 
moderate to severe neovascularisation 
(>2 vessels peripheral and internal) 
US: Initial 
(Pre-race 
1wk) & 3-days 
post-race 
Follow Up: 10 
days 
Visnes, et al. 
(2015)  
Cohort 
Study 
N = 158 (M - 74, F 
- 84) 
Mean Age - 16.8 
(range N/A) 
Junior 
Volleyball 
Patellar 
Quadriceps 
Echogenicity 
Thickness 
Vascularity 
Normal 
Abnormal: presence of  
(1) hypoechogenicity (undefined) or  
(2) thickness (undefined)  
(3) increased vascularity > stage 2 (0- 
no flow, 1- flow outside tendon,  
2- 1 or 2 vessels inside tendon, 3- 
multiple vessels inside tendon) 
US: Initial & 6-
monthly 
Follow Up 4 
years 
(average 
1.7years) 
Notes: N = number, M = male, F = female, US = ultrasound imaging, N/A = not available, incr. = increased, RCT = randomised 
controlled trial, mm = millimetres, wk = week
 33 
Table 3: Summary of CASP scores for included studies 
Cohort Studies 
  1 2 3 4 5a 5b 6a 6b 7 10 11 12 Score 
Archambault, et al. (1998)      	 	 	     75% 
Boesen, et al. (2012)             100% 
Comin, et al. (2013)   	  	 	       75% 
Cook, et al. (2000)             100% 
Cook, et al. (2001)      	       92% 
de Vos, et al. (2007)     	 	       83% 
Fredberg and Bolvig (2002)     	 	       83% 
Giombini, et al. (2013)             100% 
Gisslén and Alfredson (2005)      	   	    83% 
Gisslén, et al. (2007)      	   	    83% 
Hirschmüller, et al. (2012)        	 	     83% 
Jhingan, et al. (2011)   	  	 	       75% 
Khan, et al. (1997)             100% 
Khan, et al. (2003)   	  	 	       75% 
Malliaras, et al. (2010)   	  	 	       75% 
Ooi, et al. (2015)             100% 
Visnes, et al. (2015)             100% 
Randomised Controlled Trials 
 1 2 3 4 5  6  7 9 10 11  
de Jonge, et al. (2010)    	         90% 
Fredberg, et al. (2008)   	 	 	  	      60% 
Notes: CASP = Critical Appraisal Skills Programme, = yes, 	= no 
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Table 4: Synthesis of Evidence 
Author 
US Parameter Assessed Study 
Quality 
Was the 
criteria able to 
predict 
outcomes? 
Is the criteria 
based off the 
continuum 
model? Echogenicity Thickness Vascularisation 
Fibrillar 
Pattern 
Archambault, et al. (1998)   	 	 Good  	 
Boesen, et al. (2012) 	 	  	 Good  	 	 
Comin, et al. (2013)    	 Good 	 	 
Cook, et al. (2000)   	 	 Good  	 
Cook, et al. (2001)   	 	 Good 	 	 
de Jonge, et al. (2010) 	 	  	 Good 	 	 
de Vos, et al. (2007) 	 	  	 Good 	 	 
Fredberg and Bolvig (2002)   	 	 Good  	 
Fredberg, et al. (2008)   	 	 Good  	 
Giombini, et al. (2013)    	 Good  	 
Gisslén and Alfredson (2005)    	 Good  	 
Gisslén, et al. (2007)    	 Good  	 
Hirschmüller, et al. (2012)     	 Good 	 	 
Jhingan, et al. (2011)    	 Good 	 	 
Khan, et al. (1997)   	 	 Good  	 
Khan, et al. (2003)    	 Good 	 	 
Malliaras, et al. (2010)    	 Good  	 
Ooi, et al. (2015)    	 Good 	 	 
Visnes, et al. (2015)    	 Good  	 
Notes: US = ultrasound imaging, = yes, 	= no 
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Table 5: Classification of Echogenicity 
Author Grading/Classification Abnormal Echogenicity 
 Nominal Scale  
Comin, et al. (2013) Normal 
Abnormal: presence of [1] hypoechogenicity, or [2] increased 
thickness, or [3] vascularity, or [4] intratendon defect (all 
undefined) 
Presence of hypoechoic regions 
(undefined) 
Cook, et al. (2000) Normal 
Abnormal: presence of [1] hypoechoic region, or [2] fusiform 
swelling (both undefined) 
Presence of hypoechoic regions 
(undefined) 
Cook, et al. (2001) Normal 
Abnormal: presence of [1] hypoechoic region, or [2] fusiform 
swelling (both undefined) 
Presence of hypoechoic regions 
(undefined) 
Fredberg and Bolvig 
(2002) 
Normal 
Abnormal: presence of [1] thickening >1mm, or [2] hypoechoic 
region >1mm 
Hypoechoic region >1mm 
Giombini, et al. (2013) Normal 
Abnormal: presence of [1] focal/diffuse thickening, or [2] 
focal/diffuse hypoechogenicity, or [3] vascularity > grade 2 
Focal/Diffuse hypoechogenicity 
(undefined) 
Gisslén and Alfredson 
(2005) 
Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity > grade 2 
Presence of hypoechoic regions 
(undefined) 
Gisslén, et al. (2007) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity > grade 2 
Presence of hypoechoic regions 
(undefined) 
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Hirschmüller, et al. (2012) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypo/hyper echogenicity, or [3] vascularity > grade 1 
Presence of hyper/hypo echoic 
regions (undefined) 
Jhingan, et al. (2011) Normal 
Abnormal: presence of [1] thickening >1mm, or [2] 
hypoechogenicity >1mm, or [3] paratendon blurring, or [4] 
vascularity 
Hypoechoic region >1mm 
Khan, et al. (1997) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity (both undefined) 
Presence of hypoechoic regions 
(undefined) 
Malliaras, et al. (2010) Normal 
Abnormal: presence of [1] diffuse thickening, or [2] 
hypoechogenicity (both undefined), or [3] vascularity >1mm 
Presence of hypoechoic regions 
(undefined) 
Visnes, et al. (2015) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity > grade 2 
 
Presence of hypoechoic regions 
(undefined) 
 Ordinal Scale  
Archambault, et al. (1998) Grade 1: Normal (parallel margins, homogeneous) 
Grade 2: Enlarged tendon (bowed margins, homogeneous) 
Grade 3: Hypoechoic (with or without enlargement) 
Grade 3: Presence of hypoechoic 
regions (undefined) 
Fredberg, et al. (2008) Normal 
Slightly Abnormal: presence of [1] thickening or hypoechoic 
region 0.5-1mm in AT, and [2] thickening or hypoechoic region 
1-2mm in PT 
Severely Abnormal: presence of [1] thickening or hypoechoic 
region >1mm AT, and thickening or hypoechoic region >2mm 
in PT 
Hypoechoic region >0.5mm in AT 
Hypoechoic region >1mm in PT 
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Khan, et al. (2003) Grade 1: Normal 
Grade 2: Thickened (>6mm), homogenous echotexture 
Grade 3: Hyper/hypo echoic areas with/without thickening 
Vascularity: normal or abnormal 
Grade 3: Presence of hyper/hypo 
echoic regions (undefined) 
Ooi, et al. (2015) Grade 1: Normal 
Grade 2: Heterogeneous echotexture, bowed tendon margins, 
mild neovascularisation 
Grade 3: discrete hypoechoic areas, marked thickening, 
moderate to severe neovascularisation 
Grades 2-3: heterogeneous 
echotexture (undefined) or discrete 
hypoechoic regions (undefined) 
Notes: mm = millimetres, AT = Achilles tendon, PT = patellar tendon 
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Table 6: Classification of Tendon Thickness 
Author Grading/Classification Abnormal Thickness 
 Nominal Scales  
Comin, et al. (2013) Normal 
Abnormal: presence of [1] hypoechogenicity, or [2] increased 
thickness, or [3] vascularity, or [4] intratendon defect (all 
undefined) 
Increased thickness (undefined) 
Cook, et al. (2000) Normal 
Abnormal: presence of [1] hypoechoic region, or [2] fusiform 
swelling (both undefined) 
Fusiform swelling (undefined) 
Cook, et al. (2001) Normal 
Abnormal: presence of [1] hypoechoic region, or [2] fusiform 
swelling (both undefined) 
Fusiform swelling (undefined) 
Fredberg and Bolvig 
(2002) 
Normal 
Abnormal: presence of [1] thickening >1mm, or [2] hypoechoic 
region >1mm 
Thickening >1mm 
Giombini, et al. (2013) Normal 
Abnormal: presence of [1] focal/diffuse thickening, or [2] 
focal/diffuse hypoechogenicity, or [3] vascularity > grade 2 
Focal/Diffuse thickening (undefined) 
Gisslén and Alfredson 
(2005) 
Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity > grade 2 
Increased thickness (undefined) 
Gisslén, et al. (2007) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity > grade 2 
Increased thickness (undefined) 
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Hirschmüller, et al. (2012)  Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypo/hyper echogenicity, or [3] vascularity > grade 1 
Increased thickness (undefined) 
Jhingan, et al. (2011) Normal 
Abnormal: presence of [1] thickening >1mm, or [2] 
hypoechogenicity >1mm, or [3] paratendon blurring, or [4] 
vascularity 
Thickening >1mm 
Khan, et al. (1997) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity (both undefined) 
Increased thickness (undefined) 
Malliaras, et al. (2010) Normal 
Abnormal: presence of [1] diffuse thickening, or [2] 
hypoechogenicity (both undefined), or [3] vascularity >1mm  
Increased thickness (undefined) 
Visnes, et al. (2015) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity > grade 2 
 
Increased thickness (undefined) 
 Ordinal Scales  
Archambault, et al. (1998) Grade 1: Normal (parallel margins, homogeneous) 
Grade 2: Enlarged tendon (bowed margins, homogeneous) 
Grade 3: Hypoechoic (with or without enlargement) 
Grade 2-3: Enlarged tendon with 
bowed margins (undefined) 
Fredberg, et al. (2008) Normal 
Slightly Abnormal: presence of [1] thickening or hypoechoic 
region 0.5-1mm in AT, and [2] thickening or hypoechoic region 
1-2mm in PT 
Severely Abnormal: presence of [1] thickening or hypoechoic 
region >1mm AT, and thickening or hypoechoic region >2mm 
in PT 
Thickening >0.5mm in AT 
Thickening >1mm in PT  
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Khan, et al. (2003) Grade 1: Normal 
Grade 2: Thickened (>6mm), homogenous echotexture 
Grade 3: Hyper/hypo echoic areas with/without thickening 
Vascularity: normal or abnormal  
Tendon diameter >6mm 
Ooi, et al. (2015) Grade 1: Normal 
Grade 2: Heterogeneous echotexture, bowed tendon margins, 
mild neovascularisation 
Grade 3: discrete hypoechoic areas, marked thickening, 
moderate to severe neovascularisation 
Grade 2-3: Increased thickness 
(undefined) 
 
Notes: mm = millimetres, AT = Achilles tendon, PT = patellar tendon 
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Table 7: Classification of Vascularity 
Author Grading/Classification Abnormal Vascularity 
 Nominal Scales  
Comin, et al. (2013) Normal 
Abnormal: presence of [1] hypoechogenicity, or [2] increased 
thickness, or [3] vascularity, or [4] intratendon defect (all 
undefined) 
Presence of vascularity (undefined) 
Giombini, et al. (2013) Normal 
Abnormal: presence of [1] focal/diffuse thickening, or [2] 
focal/diffuse hypoechogenicity, or [3] vascularity >2 (0- no flow, 
1- flow outside tendon, 2- 1 or 2 vessels inside tendon, 3- 
multiple vessels inside tendon) 
Vascularity Grade 2-3: >1 vessel 
inside tendon 
Gisslén and Alfredson 
(2005) 
Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity >2 (0- no flow, 1- flow 
outside tendon, 2- 1 or 2 vessels inside tendon, 3- multiple 
vessels inside tendon) 
Vascularity Grade 2-3: >1 vessel 
inside tendon 
Gisslén, et al. (2007) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity >2 (0- no flow, 1- flow 
outside tendon, 2- 1 or 2 vessels inside tendon, 3- multiple 
vessels inside tendon) 
Vascularity Grade 2-3: >1 vessel 
inside tendon 
Hirschmüller, et al. (2012)  Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypo/hyper echogenicity, or [3] vascularity >1 (0 – no Doppler, 
1 – 1 or 2 tiny foci, 2 – <5% colour ROI, 3 – 5-24% colour ROI, 
4 – 25-49% colour ROI, 5 – >50% colour ROI) 
Vascularity Grade 1-5: >1 or 2 tiny 
foci 
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Jhingan, et al. (2011) Normal 
Abnormal: presence of [1] thickening >1mm, or [2] 
hypoechogenicity >1mm, or [3] paratendon blurring, or [4] 
vascularity 
Presence of vascularity (undefined) 
Malliaras, et al. (2010) Normal 
Abnormal: presence of [1] diffuse thickening, or [2] 
hypoechogenicity (both undefined), or [3] vascularity >1mm  
Presence of >1 vessel >1mm in 
length  
Visnes, et al. (2015) Normal 
Abnormal: presence of [1] increased thickness, or [2] 
hypoechogenicity, or [3] vascularity >2(0- no flow, 1- flow 
outside tendon, 2- 1 or 2 vessels inside tendon, 3- multiple 
vessels inside tendon) 
Vascularity Grade 2-3: >1 vessel 
inside tendon 
 Ordinal Scales  
Boesen, et al. (2012) 0 – no Doppler 
1 – 1 or 2 tiny foci 
2 – <5% colour ROI 
3 – 5-24% colour ROI 
4 – 25-49% colour ROI 
5 – >50% colour ROI 
Grade 2-5: > 1 or 2 tiny foci 
de Jonge, et al. (2010) 0 – no vessels 
1 – one vessel mostly in anterior part 
2 – one/two vessels throughout tendon 
3 – three vessels throughout tendon 
4 – >3 large tendons throughout tendon 
Grade 1-4: > 1 vessel in tendon 
de Vos, et al. (2007) 0 – no vessels 
1+ – one vessel mostly in anterior part 
2+ – one/two vessels throughout tendon 
3+ – three vessels throughout tendon 
4+ – >3 large vessels throughout tendon 
Grade 1-4: >1 vessel in tendon 
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Khan, et al. (2003) Grade 1: Normal 
Grade 2: Thickened (>6mm), homogenous echotexture 
Grade 3: Hyper/hypo echoic areas with/without thickening 
Vascularity: normal or abnormal  
Presence of vascularity (undefined) 
Ooi, et al. (2015) Grade 1: Normal 
Grade 2: Heterogeneous echotexture, bowed tendon margins, 
mild neovascularisation (1 or 2 intratendinous vessels >1mm in 
length) 
Grade 3: discrete hypoechoic areas, marked thickening, 
moderate to severe neovascularisation (>2 vessels peripheral 
and internal) 
Grade 2-3: >1 vessel >1mm in length  
Notes: ROI = region of interest, mm = millimetre
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Figure Captions List 
Figure 1: Preferred Reporting Items for Systematic Reviews and Meta-analysis 
(PRISMA) flow diagram.  
 
Figure 2: Meta-analysis results for studies using ultrasound imaging (US) to predict 
symptomatic Achilles and patellar tendinopathy. 
 
Figure 3: Meta-analysis results comparing prediction of symptomatic Achilles and 
patellar tendinopathy using 3 ultrasound imaging (US) defined parameters and 2 US 
defined parameters. 
 
Figure 4: Meta-analysis results comparing prediction of symptomatic patellar 
tendinopathy using 3 ultrasound imaging (US) defined parameters and 2 US defined 
parameters. 
 
Figure 5: Funnel plot analysis of study bias for prediction of Achilles and patellar 
tendinopathy using ultrasound imaging (US). 
 
Figure 6: Funnel plot analysis of study bias for prediction of Achilles and patellar 
tendinopathy using 3 ultrasound imaging (US) defined parameters and 2 US defined 
parameters. 
 
Figure 7: Funnel plot analysis of study bias for prediction of patellar tendinopathy 
using 3 ultrasound imaging (US) defined parameters and 2 US defined parameters. 
 
